Explore our web companion for the video featuring insights from Roshni Rao, MD FACS, Chief of Breast Surgery at Columbia University.…
Browsing: ASBRS
At the ASBrS 2025 annual meeting, Dr. Lucy Maria De La Cruz, MD, from Georgetown University Hospital, shared vital insights…
What Are CDK4/6 Inhibitors? CDK4/6 inhibitors, such as abemaciclib and ribociclib, are changing breast cancer treatment for HR+/HER2- early-stage patients.…
Sensation-preserving mastectomies are transforming breast cancer surgery. They prioritize oncologic safety and sensory recovery. In an exclusive interview, Dr. Anne…
A major study, NRG-NSABP B-51/RTOG 1304, published on June 4, 2025, in the New England Journal of Medicine, shows regional…
The I-SPY2 Trial is transforming breast cancer treatment, offering new insights into pre-surgery chemotherapy for invasive lobular breast cancer (ILC).…
Breast surgery is transforming patient care with innovative approaches. Oncoplastic breast surgery, for instance, merges art and science to improve…
At ASBrS 2025, experts showcased how MRD testing in breast cancer is revolutionizing patient care. Using Natera’s Signatera, clinicians detect circulating tumor…
By: Nathalie M. Johnson, MD – Legacy Health Partners Conference: ASBrS Dr. Nathalie M. Johnson, MD, a breast cancer specialist…
By: Dr. Kevin Hughes, MD, from MUSC Health Conference: ASBrS Introduction Dr. Kevin Hughes, MD, from MUSC Health, sheds light…
By: Dr. Erica Giblin, MD, from Ascension Medical Group Conference: ASBrS Genetic Testing Cancer In recent years, the field of…
By: Barry S. Rosen, MD – Advocate Aurora Health Conference: ASBrS 2024 In the evolving landscape of cancer treatment, ctDNA…